75 related articles for article (PubMed ID: 18594013)
1. Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer.
Papewalis C; Wuttke M; Seissler J; Meyer Y; Kessler C; Jacobs B; Ullrich E; Willenberg HS; Schinner S; Baehring T; Scherbaum WA; Schott M
Clin Cancer Res; 2008 Jul; 14(13):4298-305. PubMed ID: 18594013
[TBL] [Abstract][Full Text] [Related]
2. Amino acid-modified calcitonin immunization induces tumor epitope-specific immunity in a transgenic mouse model for medullary thyroid carcinoma.
Wuttke M; Papewalis C; Meyer Y; Kessler C; Jacobs B; Willenberg HS; Schinner S; Kouatchoua C; Baehring T; Scherbaum WA; Schott M
Endocrinology; 2008 Nov; 149(11):5627-34. PubMed ID: 18617610
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
Yamaguchi S; Tatsumi T; Takehara T; Sakamori R; Uemura A; Mizushima T; Ohkawa K; Storkus WJ; Hayashi N
Cancer; 2007 Oct; 110(7):1469-77. PubMed ID: 17685394
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma.
Papewalis C; Wuttke M; Jacobs B; Domberg J; Willenberg H; Baehring T; Cupisti K; Raffel A; Chao L; Fenk R; Seissler J; Scherbaum WA; Schott M
Horm Metab Res; 2008 Feb; 40(2):108-16. PubMed ID: 18283628
[TBL] [Abstract][Full Text] [Related]
5. Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2.
Mochimaru H; Nagai N; Hasegawa G; Kudo-Saito C; Yaguchi T; Usui Y; Kurihara T; Koto T; Satofuka S; Shinoda H; Ozawa Y; Tsubota K; Kawakami Y; Ishida S
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4795-801. PubMed ID: 17898306
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
9. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
10. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
[TBL] [Abstract][Full Text] [Related]
11. Chromogranin A as potential target for immunotherapy of malignant pheochromocytoma.
Papewalis C; Kouatchoua C; Ehlers M; Jacobs B; Porwol D; Schinner S; Willenberg HS; Anlauf M; Raffel A; Eisenhofer G; Neumann HP; Bornstein SR; Scherbaum WA; Schott M
Mol Cell Endocrinol; 2011 Mar; 335(1):69-77. PubMed ID: 20600588
[TBL] [Abstract][Full Text] [Related]
12. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
13. Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination.
Pfragner R; Skofitsch G; Höger H; Jech M; Rinner B; Siegl V; Niederle B; Gnant M; Friedl J; Stift A
Anticancer Res; 2005; 25(6B):4225-30. PubMed ID: 16309220
[TBL] [Abstract][Full Text] [Related]
14. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
Shojaeian J; Jeddi-Tehrani M; Dokouhaki P; Mahmoudi AR; Ghods R; Bozorgmehr M; Nikoo S; Bayat AA; Akhondi MM; Ostadkarampour M; Rezania S; Zarnani AH
J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973
[TBL] [Abstract][Full Text] [Related]
15. Expression of v-Ha-ras driven by the calcitonin/calcitonin gene-related peptide promoter: a novel transgenic murine model for medullary thyroid carcinoma.
Johnston D; Hatzis D; Sunday ME
Oncogene; 1998 Jan; 16(2):167-77. PubMed ID: 9464534
[TBL] [Abstract][Full Text] [Related]
16. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination.
Kim SG; Park MY; Kim CH; Sohn HJ; Kim HS; Park JS; Kim HJ; Oh ST; Kim TG
Vaccine; 2008 Nov; 26(50):6433-40. PubMed ID: 18812201
[TBL] [Abstract][Full Text] [Related]
17. Memory Th1 cells augment tumor-specific CTL following transcutaneous peptide immunization.
Hosoi A; Takeda Y; Furuichi Y; Kurachi M; Kimura K; Maekawa R; Takatsu K; Kakimi K
Cancer Res; 2008 May; 68(10):3941-9. PubMed ID: 18483280
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
19. Antigens expressed by myelinating glia cells induce peripheral cross-tolerance of endogenous CD8+ T cells.
Schildknecht A; Probst HC; McCoy KD; Miescher I; Brenner C; Leone DP; Suter U; Ohashi PS; van den Broek M
Eur J Immunol; 2009 Jun; 39(6):1505-15. PubMed ID: 19462379
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.
Hamdy S; Molavi O; Ma Z; Haddadi A; Alshamsan A; Gobti Z; Elhasi S; Samuel J; Lavasanifar A
Vaccine; 2008 Sep; 26(39):5046-57. PubMed ID: 18680779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
